Seed Health leverages computational biology and ultra-deep sequencing to analyze host-microbe interactions, enabling the development of prebiotics, probiotics, and synbiotics that enhance gut health and overall well-being. The company addresses the lack of effective probiotic solutions by commercializing scientifically validated products that optimize the human microbiome across various life stages.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVTCFounders
Product
Problem
Existing prebiotic, probiotic, and synbiotic solutions often lack rigorous scientific validation and fail to adequately address the complex interactions between the human microbiome and overall health. Traditional methods for analyzing host-microbe interactions are limited by primitive tools, small data sets, and shallow sequencing, hindering the development of truly effective microbiome-based interventions.
Solution
Seed Health leverages a computational biology platform and ultra-deep sequencing to analyze host-microbe interactions, enabling the development of scientifically validated prebiotics, probiotics, and synbiotics. The company constructs proprietary data clouds to elucidate these interactions, providing insights into the microbiome's role in human health. This platform facilitates the discovery, development, and clinical validation of microbiome-based solutions across various life stages, from infancy to aging. Seed Health's approach extends beyond human health to address environmental challenges through its SeedLabs initiative, exploring microbial innovations for carbon capture, plastic upcycling, and honey bee resilience.
Target Audience
The primary audience includes individuals seeking to optimize their gut health and overall well-being through scientifically validated microbiome-based interventions, as well as researchers and clinicians in the fields of microbiology, gastroenterology, and dermatology.
Features
- End-to-end platform encompassing discovery, development, clinical validation, and go-to-market strategies
- Multi-omics approach screening for unique and redundant microbial genes at the level of single nucleotide polymorphisms (SNPs)
- Chemistry, Manufacturing, and Controls (CMC) to validate viability, stability, potency, and consistency of formulations
- Human data generation through double-blind, randomized controlled trials (RCTs)
- Deep metagenomic, metatranscriptomic, and metabolomic analyses in microbiome and host
- Scalable model for omnichannel distribution and clinician engagement
- Biomaterials-based packaging systems and carbon-negative programs